Prev Close | 120.75 |
Open | 121.18 |
Day Low/High | 120.40 / 122.48 |
52 Wk Low/High | 74.51 / 121.84 |
Volume | 10.13M |
Avg Volume | 4.92M |
Prev Close | 120.75 |
Open | 121.18 |
Day Low/High | 120.40 / 122.48 |
52 Wk Low/High | 74.51 / 121.84 |
Volume | 10.13M |
Avg Volume | 4.92M |
Exchange | NYSE |
Shares Outstanding | 1.06B |
Market Cap | 126.75B |
P/E Ratio | 38.23 |
Div & Yield | 2.58 (1.88%) |
Once the safest stocks in the book, the big-cap drug companies are now toxic.
LLY has made a good run this year and now looks like it will correct a bit.
There is clear divergence between the best and the worst performers in each sector this earnings season.
There are concerns that interest rates may start to impact new car sales.
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
This is a market driven by macro matters and is not as favorable to stock pickers right now.
The stock still needs to do more work to be convincing.
Straying from these names could land you in quicksand as the 4th quarter begins.
Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.
The limited technical data for the recent Eli Lilly spinoff indicate buyers came in early and appear to be holding.
The weekly breakout is pretty impressive on the charts, so let's take a look.
The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Don't buy up when there's nothing but rampant pin action.
Here are some options strategies for this FANG name into tomorrow's report.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
All three major averages closed Thursday's session in positive territory.
Forward looking valuations, except for Nvidia, are very low.
I think M&A activity will pick up markedly going forward across the industry.
For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.
Traders should stay alert and nimble with LLY stock.
The price of LLY has climbed and the bearish price target on the Point and Figure chart is off the table.
Consider this LLY bullishly biased vertical call spread expiring in June.
We could be poised for even a further advance PROVIDED that we stay oversold.